Regulatory approval
Published by the Health Canada.
Health Canada approved nilotinib for the treatment of pediatric patients 2 years of age and older with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.
This is written in the approval document as:
TASIGNA (nilotinib) 150 mg and 200 mg capsules are indicated for the treatment of pediatric patients 2 years of age and older with Ph+ CML-CP with resistance or intolerance to prior therapy including imatinib.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HC (1) | BCR::ABL1 | Chronic Myelogenous Leukemia | Nilotinib | |
| HC (1) | BCR::ABL1 | Chronic Myeloid Leukemia, BCR-ABL1+ | Nilotinib |